To date, the pathways most commonly implicated in ER + breast cancers are AKT signaling (including PIK3CA), DNA damage and apoptosis (including TP53) and transcription regulation (containing GATA3, TBX3). This evidence concerns the gene GATA3 and breast carcinoma.